Control and blinding: Part C was an open-label extension in which all participants received study drug, and the sponsor gave it a separate registration because of its different study design.
Mixed population and dosing: Part C enrolled 66 participants, comprising 35 LEMBAZ-treated participants from Parts A and B, 18 treatment-naïve participants, and 13 LEMBAZ-treated patients from Trial 2. The dose could be adjusted between 400 mg and 900 mg at the investigator's discretion, and rollover participants from Study 13-CH-0001 received an amended dose and/or regimen.
Missing efficacy collection: the planned efficacy endpoints included the NPC-SS composite and the EQ-5D-3L. Following a determination of a negative benefit/risk balance on 20 January 2021, the objective of Part C was changed to longer-term safety and tolerability only, and efficacy endpoints after 20 January 2021 were not reported.
Early termination: the sponsor discontinued the development program and terminated Part C. No participant completed the study (0 of 18 treatment-naive, 0 of 13 previously treated in phase I, and 0 of 35 previously treated in Part A/B); termination by sponsor or regulatory authorities accounted for 8, 4, and 13 participants and withdrawal by subject for 4, 9, and 13.
Selective continuation: after 21 June 2021, only subjects who appeared to be benefiting in the investigator's assessment, and who understood that no significant differences were seen between adrabetadex and sham on any efficacy measure in the randomized trial, could continue treatment.
Substudies: the planned European plasma and CSF pharmacokinetic substudy of administration through the device was not conducted because no subjects consented.
VTS-270-302 continuation study: planned for approximately 7 subjects, it enrolled 2, was terminated early by the sponsor, did not perform efficacy assessments or analyze existing efficacy data, and reported no baseline data to maintain participant confidentiality.